睿知中国医院研究地图
候选清单

正在招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由中山大学孙逸仙纪念医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07806292,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. At least one measurable lesion as defined by the following criteria: the longest diameter ≥ 10 mm for non-nodal lesions, or the short-axis diameter ≥ 15 mm for nodal lesions; confirmed unresectable HCC; Child-Pugh liver function score ≤ 7.

    入选标准第 3 条

  3. Receipt of other investigational drugs or medical devices within 4 weeks prior to the first dose; or prior use of anti-tumor indicated drugs where less than 2 weeks or 5 drug half-lives (whichever is longer) have elapsed between the completion of previous treatment and the administration of the study drug, and adverse events caused by prior treatment have not recovered to ≤ CTCAE Grade 1.

    排除标准第 15 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

    入选标准第 7 条

  5. Patients with a second primary cancer or multiple malignancies, except for HCC, carcinoma in situ of the cervix, and non-melanoma skin cancer, or a history of other malignancies previously diagnosed and explicitly cured for at least 5 years with no evidence of subsequent recurrence.

    排除标准第 4 条

    Active hepatitis C (i.e., anti-HCV positive or HCV-RNA positive with abnormal liver function); known history of HIV infection.

    排除标准第 14 条

  6. Pregnant or lactating women; sexually active men or women of childbearing potential who are unwilling or unable to use effective contraception.

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07806292,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age between 18 and 75 years, regardless of gender.
  2. Confirmed diagnosis of unresectable hepatocellular carcinoma (HCC) according to both the China Liver Cancer (CNLC) staging criteria and the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria.
  3. At least one measurable lesion as defined by the following criteria: the longest diameter ≥ 10 mm for non-nodal lesions, or the short-axis diameter ≥ 15 mm for nodal lesions; confirmed unresectable HCC; Child-Pugh liver function score ≤ 7.
  4. Naive to any local (ablation, hepatic arterial embolization/infusion therapy, liver transplantation) or systemic therapy (chemotherapy and/or molecular targeted therapy, immunotherapy; antiviral therapy excluded) for HCC at initial diagnosis, or patients with intrahepatic recurrence after previous radical resection.
  5. Expected survival time ≥ 12 weeks.
  6. No anti-HCC drugs (including modern traditional Chinese medicine preparations indicated for HCC: Lentinan Injection, Kanglaite Injection or Soft Capsules, Aidi or Kangsaidi Injection, Propaneed Oil, Huai'er Granules, and Ganfule Tablets) administered within 2 weeks prior to the first dose.
  7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
  8. HBV DNA < 10\^4 copies/ml (2000 IU/ml). If HBV DNA ≥ 10\^4 copies/ml, antiviral therapy must be initiated first and continued until HBV DNA drops below 10\^4 copies/ml before entering the study, along with ongoing antiviral medication and monitoring of liver function and HBV viral load.
  9. Normal function of major organs, meeting the following criteria:
  10. The patient voluntarily consents to enrollment, signs the written informed consent form (ICF), and is able to comply with the required treatment and follow-up visits according to the protocol.

排除标准:Exclusion Criteria:

  1. Histologically confirmed fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma (HCC-ICC).
  2. Symptomatic moderate to massive pleural effusion/ascites.
  3. Obstructive jaundice, liver failure, or hepatic encephalopathy.
  4. Patients with a second primary cancer or multiple malignancies, except for HCC, carcinoma in situ of the cervix, and non-melanoma skin cancer, or a history of other malignancies previously diagnosed and explicitly cured for at least 5 years with no evidence of subsequent recurrence.
  5. Active bleeding or coagulation abnormalities (Prothrombin Time, PT > 16 s; Activated Partial Thromboplastin Time, APTT > 43 s; International Normalized Ratio, INR ≥ 2), bleeding tendency, or currently receiving thrombolytic, anticoagulant, or antiplatelet therapy.
  6. Concomitant use of medications that may prolong the QTc interval and/or induce Torsades de Pointes (TdP), or affect the metabolism of chemotherapeutic agents.
  7. Pregnant or lactating women; sexually active men or women of childbearing potential who are unwilling or unable to use effective contraception.
  8. Any significant clinical or laboratory abnormalities that, in the opinion of the investigator, would affect the safety evaluation, such as: uncontrolled active infection (> NCI-CTCAE v5.0 Grade 2), uncontrolled diabetes (> NCI-CTCAE v5.0 Grade 2), hypertension not controlled to below the specified range (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg) despite treatment with two or more antihypertensive drugs, peripheral neuropathy ≥ Grade 2 (NCI-CTCAE v5.0), congestive heart failure ≥ Grade 2 (NCI-CTCAE v5.0), myocardial infarction within 6 months, or thyroid dysfunction (> NCI-CTCAE v5.0 Grade 2), etc.
  9. History of brain metastases, subdural metastasis, or severe mental illness; patients suspected of central nervous system (CNS) metastases must be excluded by cranial MRI.
  10. History of gastrointestinal bleeding or definite predisposition to gastrointestinal bleeding within the past 3 months, such as known active ulcer lesions, or fecal occult blood ≥ ++ (not eligible for enrollment); if persistent fecal occult blood is positive, a gastroscopy examination is required.
  11. Severe gastric fundus/esophageal wall varices requiring interventional treatment.
  12. Occurrence of abdominal or gastrointestinal perforation or intra-abdominal abscess within 4 weeks prior to the first dose.
  13. Significant abnormality in glomerular filtration rate (estimated creatinine clearance < 60 ml/min or serum creatinine > 1.5 × ULN).
  14. Active hepatitis C (i.e., anti-HCV positive or HCV-RNA positive with abnormal liver function); known history of HIV infection.
  15. Receipt of other investigational drugs or medical devices within 4 weeks prior to the first dose; or prior use of anti-tumor indicated drugs where less than 2 weeks or 5 drug half-lives (whichever is longer) have elapsed between the completion of previous treatment and the administration of the study drug, and adverse events caused by prior treatment have not recovered to ≤ CTCAE Grade 1.

引自 ClinicalTrials.gov, NCT07806292, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07806292,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07806292